Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Interest Expense : $-0.17 Mil (TTM As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cancer Prevention Pharmaceuticals's interest expense for the three months ended in Mar. 2016 was $ -0.17 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2016 was $-0.17 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cancer Prevention Pharmaceuticals's Operating Income for the three months ended in Mar. 2016 was $ -2.13 Mil. Cancer Prevention Pharmaceuticals's Interest Expense for the three months ended in Mar. 2016 was $ -0.17 Mil. Cancer Prevention Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cancer Prevention Pharmaceuticals Interest Expense Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Interest Expense Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Interest Expense

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Interest Expense	Get a 7-Day Free Trial			-	-	-	-	-0.17

Cancer Prevention Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17 Mil.

Cancer Prevention Pharmaceuticals (AMEX:CPP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cancer Prevention Pharmaceuticals's Interest Expense for the three months ended in Mar. 2016 was $-0.17 Mil. Its Operating Income for the three months ended in Mar. 2016 was $-2.13 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2016 was $5.60 Mil.

Cancer Prevention Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2016 is calculated as

Cancer Prevention Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.